These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21252986)

  • 1. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
    Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ
    Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
    Yong AS; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
    Blood; 2007 Jul; 110(2):770-5. PubMed ID: 17412886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens.
    Steele JC; Torr EE; Noakes KL; Kalk E; Moss PA; Reynolds GM; Hubscher SG; van Lohuizen M; Adams DH; Young LS
    Br J Cancer; 2006 Nov; 95(9):1202-11. PubMed ID: 17024127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Wang ZD; Li D; Huang XJ
    Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
    Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA
    Blood; 2012 Jan; 119(2):494-502. PubMed ID: 22101899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
    Rezvani K; Grube M; Brenchley JM; Sconocchia G; Fujiwara H; Price DA; Gostick E; Yamada K; Melenhorst J; Childs R; Hensel N; Douek DC; Barrett AJ
    Blood; 2003 Oct; 102(8):2892-900. PubMed ID: 12829610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
    Mohty M; Szydlo RM; Yong AS; Apperley JF; Goldman JM; Melo JV
    Blood; 2008 Sep; 112(5):2163-6. PubMed ID: 18565849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
    Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
    Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
    Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
    Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.
    Ochi T; Fujiwara H; Suemori K; Azuma T; Yakushijin Y; Hato T; Kuzushima K; Yasukawa M
    Blood; 2009 Jan; 113(1):66-74. PubMed ID: 18820130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
    Rezvani K; Yong AS; Savani BN; Mielke S; Keyvanfar K; Gostick E; Price DA; Douek DC; Barrett AJ
    Blood; 2007 Sep; 110(6):1924-32. PubMed ID: 17505014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.
    Norde WJ; Overes IM; Maas F; Fredrix H; Vos JC; Kester MG; van der Voort R; Jedema I; Falkenburg JH; Schattenberg AV; de Witte TM; Dolstra H
    Blood; 2009 Mar; 113(10):2312-23. PubMed ID: 19074734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
    Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
    Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
    Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M
    Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.
    Rizo A; Horton SJ; Olthof S; Dontje B; Ausema A; van Os R; van den Boom V; Vellenga E; de Haan G; Schuringa JJ
    Blood; 2010 Nov; 116(22):4621-30. PubMed ID: 20724541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
    Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
    Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.